Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Related records

Trials (27)

• A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
• A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
• A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
• A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
• A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
• A Study of GR1803 in Systemic Lupus Erythematosus
• A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
• A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
• A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
• A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
• A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.
• A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
• A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult
• A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
• Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
• GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
• GR1803 Injection in Patients With RRMM
• Phase I Trial of GR1803 Injection in Patients With RRMM
• Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis